Latest Breaking News On - Prof markus ollert - Page 1 : comparemela.com

Luxembourg Researchers Find Allergy-Induced Inflammation Combats Brain Tumour Progression

Luxembourg Researchers Find Allergy-Induced Inflammation Combats Brain Tumour Progression
chronicle.lu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chronicle.lu Daily Mail and Mail on Sunday newspapers.

Markus ollertLuxembourg institute of healthLuxembourg instituteProf markus ollert

New study further advances the treatment of chronic pain

Scientists from the Immuno-Pharmacology and Interactomics group at the Luxembourg Institute of Health (LIH), in collaboration with the Center for Drug Discovery at RTI International (RTI), have demonstrated that conolidine, a natural painkiller derived from the pinwheel flower and traditionally used in Chinese medicine, interacts with the newly identified opioid receptor ACKR3/CXCR7 that regulates opioid peptides naturally produced in the brain. The researchers also developed a synthetic analogue of conolidine, RTI-5152-12, which displays an even greater activity on the receptor.

Andy chevignOjas namjoshiMartyna szpakowskaMarkus ollertMinistry of higher educationDepartment of infectionNature communicationsImmunity of the luxembourg institute healthEuropean commissionLuxembourg national research fundLuxembourg instituteDrug discoverySignal transductionTargeted therapyProf markus ollertHigher education

Research opens alternative therapeutic avenues for treatment of chronic pain

Building on their previous findings, scientists from the Immuno-Pharmacology and Interactomics group at the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH), in collaboration with the Center for Drug Discovery at RTI International (RTI), a nonprofit research institute, have demonstrated that conolidine, a natural painkiller derived from the pinwheel flower and traditionally used in Chinese medicine, interacts with the newly identified opioid receptor ACKR3/CXCR7 that regulates opioid peptides naturally produced in the brain.

Andy chevignOjas namjoshiMartyna szpakowskaMarkus ollertEmily hendersonMinistry of higher educationDepartment of infectionNature communicationsImmunity of the luxembourg institute healthEuropean commissionLuxembourg national research fundLuxembourg instituteDrug discoverySignal transductionTargeted therapyProf markus ollert

New Immunotherapy Helps Treat Cat Allergy

New Immunotherapy Helps Treat Cat Allergy by Angela Mohan on February 8, 2021 at 3:08 PM High doses of CpG oligonucleotide helps in successfully modulating the immune system s allergic response to the main cat allergen Fel d 1, inducing a tolerance-promoting reaction and reverting the main hallmarks of cat allergy, as per researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH). The researchers analysed the molecular mechanisms underlying this tolerance and proposed a pre-clinical allergen-specific immunotherapy approach to improve the treatment and control of this common type of allergy. The full study results were published recently in the renowned international journal

Markus ollertDepartment of infectionImmunity of the luxembourg institute healthEuropean academy of allergyLuxembourg instituteEuropean academyClinical immunologyNatural killerTumour necrosis factorProf markus ollertRight over the counter drugsSeasonal allergyPollen allergyremediesEvaluationstay well thisSpecific adjuvant moleculeEuropean academy of allergy and clinical immunology

Novel immunotherapy approach to treat cat allergy

Credit: Copyright: LIH Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) brought forward the potential of high doses of a specific adjuvant molecule, namely CpG oligonucleotide, in successfully modulating the immune system s allergic response to the main cat allergen Fel d 1, thereby inducing a tolerance-promoting reaction and reverting the main hallmarks of cat allergy. The researchers analysed the molecular mechanisms underlying this tolerance and proposed a pre-clinical allergen-specific immunotherapy approach to improve the treatment and control of this common type of allergy. The full study results were published recently in the renowned international journal

Markus ollertDepartment of infectionImmunity of the luxembourg institute healthEuropean academy of allergyLuxembourg instituteEuropean academyClinical immunologyNatural killerTumour necrosis factorProf markus ollertதுறை ஆஃப் தொற்றுநோய் எதிர்ப்பு சக்தி ஆஃப் தி லக்ஸம்பர்க் நிறுவனம் ஆரோக்கியம்ஐரோப்பிய கலைக்கழகம் ஆஃப் ஒவ்வாமைலக்ஸம்பர்க் நிறுவனம்ஐரோப்பிய கலைக்கழகம்மருத்துவ நோயெதிர்ப்பு